心力衰竭与COVID-19胸部CT特征及临床特点对比
本研究为回顾性研究,纳入中南大学湘雅二医院2019年12月1日至2020年2月15日间7例心力衰竭患者与12例COVID-19患者,比较两组基线临床特征及肺部CT影像特征。结果示COVID-19组流行病学接触史、发热或呼吸道症状比例更高,心力衰竭组心血管基础疾病及心功能受损比例更高,影像学上病变分布、形态及肺静脉扩张情况存在差异。
要点
- COVID-19组流行病学接触史及发热或呼吸道症状比例显著高于心力衰竭组。
- 心力衰竭组肺部病变更呈中央型及阶梯状分布,且小肺静脉扩张比例更高。
- COVID-19组肺部病变呈圆形或类圆形比例高于心力衰竭组。
核心结论
- COVID-19患者具有流行病学接触史,发热和呼吸道症状明显。
- 心力衰竭与COVID-19肺部CT有相似之处,但病变分布特点、病变形态和肺静脉扩张情况不同。
研究设计与样本
- 本研究为回顾性研究,纳入中南大学湘雅二医院2019年12月1日至2020年2月15日间心力衰竭患者7例、COVID-19患者12例,排除病例资料不全者。
主要发现
- 两组年龄、性别差异无统计学意义(P均>0.05)。
- COVID-19组流行病学接触史比例高于心力衰竭组(12/12比0,P<0.001)。
- COVID-19组发热或呼吸道症状比例高于心力衰竭组(12/12比4/7,P=0.013)。
- COVID-19组合并心血管基础疾病比例少于心力衰竭组(2/12比7/7,P<0.001),心功能受损比例少于心力衰竭组(0比7/7,P<0.001)。
- 心力衰竭组肺部病变呈中央型及阶梯状比例高于COVID-19组(4/7比1/12,P=0.04),小肺静脉扩张比例更高(3/7比0,P=0.013)。
关键数值与推荐
- 两组均可有磨玻璃影及小叶间隔增厚。
- COVID-19组肺部病变呈圆形或类圆形比例高于心力衰竭组(9/12比2/7,P=0.048)。
- 心力衰竭组经有效抗心力衰竭治疗后肺部病变会快速改善。
临床怎么用
- 结合流行病学接触史、发热及呼吸道症状区分COVID-19与心力衰竭。
- 关注肺部CT病变分布、形态及肺静脉扩张情况以帮助鉴别。
- 心力衰竭患者经有效抗心力衰竭治疗后肺部病变可快速改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To identify the characteristics including clinical features and pulmonary computed tomography (CT) features of heart failure and COVID-19. Methods: This study was a retrospective study. A total of 7 patients with heart failure and 12 patients with COVID-19 in the Second Xiangya Hospital of Central South University between December 1, 2019 and February 15, 2020 were enrolled. The baseline clinical and imaging features of the two groups were statistically analyzed. Results: There was no significant difference in age and sex between the two groups(both P>0.05), but the incidence of epidemiological contact history, fever or respiratory symptoms in the COVID-19 group was significantly higher than that in the heart failure group (12/12 vs. 0, P<0.001; 12/12 vs. 4/7, P=0.013). While the proportion of cardiovascular diseases and impaired cardiac function was significantly less than that of the heart failure group(2/12 vs.7/7, P<0.001;0 vs.7/7, P<0.001). For imaging features, both groups had ground-glass opacity and thickening of interlobular septum, but the ratio of central and gradient distribution was higher in patients with heart failure than that in patients with COVID-19 (4/7 vs. 1/12, P=0.04). In heart failure group, the ratio of the expansion of pulmonary veins was also higher (3/7 vs. 0,P=0.013), and the lung lesions can be significantly improved after effective anti-heart failure treatment. Besides, there were more cases with rounded morphology in COVID-19 group(9/12 vs. 2/7, P=0.048). Conclusions: More patients with COVID-19 have epidemiological history and fever or respiratory symptoms. There are significant differences in chest CT features, such as enlargement of pulmonary veins, lesions distribution and morphology between heart failure and COVID-19. 目的: 对比心力衰竭及新型冠状病毒肺炎(COVID-19)患者临床及肺部影像学特征,总结二者的鉴别要点。 方法: 本研究为回顾性研究。纳入中南大学湘雅二医院于2019年12月1日至2020年2月15日间收治的心力衰竭及COVID-19患者,排除病例资料不全者,共纳入心力衰竭患者7例,COVID-19患者12例。比较两组的基线临床特征(包括性别、年龄、病史、实验室检查等)及肺部CT影像学特征。 结果: 两组间年龄、性别差异无统计学意义(P均>0.05),COVID-19组流行病学接触史、发热或呼吸道症状比例明显高于心力衰竭组(12/12比0,P<0.001;12/12比4/7,P=0.013);合并心血管基础疾病、心功能受损比例则明显少于心力衰竭组(2/12比7/7,P<0.001;0比7/7,P<0.001)。影像学方面,两组患者都可有磨玻璃影及小叶间隔增厚的特点。但与COVID-19组比较,心力衰竭患者肺部病变呈中央型及阶梯状的比例(4/7比1/12,P=0.04)及小肺静脉扩张比例更高(3/7比0,P=0.013),且经有效抗心力衰竭治疗后肺部病变会快速改善。此外,COVID-19患者肺部病变呈圆形或类圆形的比例高于心力衰竭患者(9/12比2/7,P=0.048)。 结论: COVID-19患者具有流行病学接触史,发热和呼吸道症状明显。在肺部CT影像学表现上,二者有相似之处,但病变分布特点、病变形态和肺静脉扩张情况有不同之处。.
引用
- Zhu ZW, Tang JJ, Chai XP, et al. [Comparison of heart failure and COVID-19 in chest CT features and clinical characteristics]. Zhonghua Xin Xue Guan Bing Za Zhi. 2020. PMID: 32129583. doi:10.3760/cma.j.cn112148-20200218-00093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。